Neon Therapeutics

Neon Therapeutics is a clinical-stage immuno-oncology company and specializes in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. It develops therapies that target abnormal proteins called neoantigens, which are produced by cancer cells. Its programs are designed to leverage multiple facets of the immune response to elicit potent immune attack of tumors, with the aim of providing durable response to patients in need.

Employee Rating

4.5More
StateClosed
TypeSubsidiary
Parent CompanyBioNTech
HQCambridge, MA, US
Founded2015
Websiteneontherapeutics.com
Cybersecurity ratingFMore
Neon Therapeutics was founded in 2015 and is headquartered in Cambridge, MA, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Neon Therapeutics

Hugh ODowd

Hugh ODowd

Chief Executive Officer
Ed Fritsch

Ed Fritsch

Founder
Richard Gaynor

Richard Gaynor

President of Research & Development
Robert Bazemore

Robert Bazemore

President and CEO, Epizyme
Kelledy Manson

Kelledy Manson

Vice President of Product Development
Cary Pfeffer

Cary Pfeffer

Chairman; Partner, Third Rock Ventures
Show more

Neon Therapeutics Office Locations

Neon Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
40 Erie St #110
Show all (1)

Neon Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2015

Total Funding

$161 m

Investors

In total, Neon Therapeutics had raised $161 m. Neon Therapeutics is a subsidiary of BioNTech

Neon Therapeutics Revenue

Annual
USDFY, 2018FY, 2019

General and administrative expense

18.3m21.4m

R&D expense

60.4m59.7m

Operating expense total

78.7m81.1m

EBIT

(78.7m)(81.1m)
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

General and administrative expense

4.3m4.6m5.4m5.6m5.1m7.2m

R&D expense

14.8m14.4m16.2m16.7m14.1m9.4m

Operating expense total

19.1m19.1m21.6m22.3m19.3m16.7m

EBIT

(19.1m)(19.1m)(21.6m)(22.3m)(19.3m)(16.7m)
Annual
USDFY, 2018FY, 2019

Cash

52.7m29.4m

Prepaid Expenses

2.1m1.8m

Current Assets

105.4m31.2m

PP&E

8.2m7.1m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

130.8m60.8m49.3m46.3m44.3m15.0m

Prepaid Expenses

1.6m2.3m2.3m2.0m2.0m2.0m

Current Assets

140.2m124.0m83.6m63.0m46.3m17.0m

PP&E

7.6m8.0m8.5m8.0m7.7m6.7m
Annual
USDFY, 2018FY, 2019

Net Income

(76.9m)(79.8m)

Depreciation and Amortization

1.6m

Accounts Payable

2.0m(2.3m)

Cash From Operating Activities

(63.4m)(73.4m)
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(35.4m)(53.8m)(21.0m)(43.0m)(61.9m)(16.6m)

Depreciation and Amortization

692.0k1.1m415.0k1.3m

Accounts Payable

(1.1m)490.0k(1.3m)(2.1m)1.3m

Cash From Operating Activities

(29.6m)(45.5m)(21.2m)(41.2m)(57.9m)(14.3m)
USDQ2, 2018

Financial Leverage

1.1 x
Show all financial metrics

Neon Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

F

58/100

SecurityScorecard logo

Neon Therapeutics Online and Social Media Presence

Embed Graph

Neon Therapeutics News and Updates

SHAREHOLDER ALERT: WeissLaw LLP Investigates Neon Therapeutics, Inc.

NEW YORK, April 10, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Neon Therapeutics, Inc. ("NTGN" or the "Company") (NASDAQ: NTGN) in connection with the proposed acquisition of the Company...

Thinking about buying stock in BioNTech, Chesapeake Energy, Digital Realty, Neon Therapeutics, or Waitr?

NEW YORK, March 18, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BNTX, CHK, DLR, NTGN, and WTRH. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Neon Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

CAMBRIDGE, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN) today reported financial results for the fourth quarter and full-year ended December 31, 2019 and provided a business update.

Precision Medicine Market: Industry Analysis and Detailed Profiles of Neon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG, PERSONALIS INC, GENOCEA BIOSCIENCES, INC | Data Bridge Market Research

SAN FRANCISCO, Dec. 6, 2019 /PRNewswire/ -- The perfect way to anticipate what future holds is to understand the trend today and hence Global Precision Medicine Market report has been structured by chewing over numerous fragments of the present and upcoming market scenario. The report...

Shares of Neon Therapeutics rise on restructuring plans

Shares of Neon Therapeutics were up 19% in after-hours trading Wednesday after the company announced a corporate restructuring that includes cutting 24% of its workforce. Neon, which employs about 100 workers, now plans to focus on developing T-cell therapies and is halting new spending on its canc…

Neon Therapeutics Reports First Quarter 2019 Financial Results and Provides Clinical Update

Advancing a class-leading position in neoantigen-based therapies with ongoing progress across its multiple clinical-stage programs, pre-clinical pipeline and bioinformatics engine
Show more

Neon Therapeutics Blogs

Neon Therapeutics Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01

Neon Therapeutics Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01 Content Import Wed, 12/18/2019 - 08:01 Neon Therapeutics Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell …

Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs

Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs Content Import Wed, 11/20/2019 - 16:06 Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs November 20, 2019 at 4:05 PM EST This release is a backfill from a News Wir…

Neon Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights

Neon Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights Content Import Tue, 11/12/2019 - 07:01 Neon Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights November 12, 2019 at 7:00 AM EST This release is a …

Neon Therapeutics Announces Updated Data Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Neon Therapeutics Announces Updated Data Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting Content Import Fri, 11/08/2019 - 07:00 Neon Therapeutics Announces Updated Data Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8, …

Neon Therapeutics Reports Second Quarter 2019 Financial Results

Planning to present more detailed data from NT-001 clinical trial evaluating NEO-PV-01 in advanced or metastatic melanoma, non-small cell lung and bladder cancers at an upcoming medical society meeting Announces U.S. Food & Drug Administration ( FDA ) clearance of Neon’s Investigational New Drug

Neon Therapeutics’ Personal Neoantigen Vaccine Study Demonstrates Prolonged Progression-Free Survival in Advanced or Metastatic Melanoma, Non-Small Cell Lung and Bladder Cancers

Neon Therapeutics’ Personal Neoantigen Vaccine Study Demonstrates Prolonged Progression-Free Survival in Advanced or Metastatic Melanoma, Non-Small Cell Lung and Bladder Cancers Content Import Mon, 07/15/2019 - 06:01 Neon Therapeutics’ Personal Neoantigen Vaccine Study Demonstrates Prolong…
Show more

Neon Therapeutics Frequently Asked Questions

  • When was Neon Therapeutics founded?

    Neon Therapeutics was founded in 2015.

  • Who are Neon Therapeutics key executives?

    Neon Therapeutics's key executives are Hugh ODowd, Ed Fritsch and Richard Gaynor.

  • How many employees does Neon Therapeutics have?

    Neon Therapeutics has 71 employees.

  • Who are Neon Therapeutics competitors?

    Competitors of Neon Therapeutics include BC Cancer, Asian Institute of Medical Sciences and Genetron Health.

  • Where is Neon Therapeutics headquarters?

    Neon Therapeutics headquarters is located at 40 Erie St #110, Cambridge.

  • Where are Neon Therapeutics offices?

    Neon Therapeutics has an office in Cambridge.

  • How many offices does Neon Therapeutics have?

    Neon Therapeutics has 1 office.